Language selection

Search

Details for: COMIRNATY - PREVIOUSLY/AUPARAVANT - PFIZER-BIONTECH COVID-19 VACCINE

Company: BIONTECH MANUFACTURING GMBH

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02522454COMIRNATYTOZINAMERAN10 MCG / 0.2 MLSUSPENSIONINTRAMUSCULAR
02509210COMIRNATYTOZINAMERAN30 MCG / 0.3 MLSUSPENSIONINTRAMUSCULAR

Summary Reports

Summary Basis of Decision
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19
Public Release of Clinical Information - COMIRNATY
Public Release of Clinical Information - COMIRNATY (ages 12 - 15)
Product Monograph

Consumer Information

This information was provided by the drug’s manufacturer when this drug product was approved for sale in Canada. It is designed for consumers and care givers. It is a summary of information about the drug and will not tell you everything about the drug. Contact your doctor or pharmacist if you have any questions about the drug.

What the medication is used for

COMIRNATY is a vaccine used to prevent COVID-19 disease caused by the SARS-CoV-2 virus.

COMIRNATY can be given to people from 5 years of age and older.

What it does

The vaccine causes our body to produce protection (such as antibodies) that prevent the COVID-19 virus from entering our cells to make us sick. The vaccine uses a new method (messenger RNA - mRNA, the genetic code for a piece of the virus) to help our bodies make protection against the virus. The vaccine is given by injection with a needle in the upper arm and will require two doses given 3 weeks apart.

You cannot get COVID-19 from the vaccine.

As with any vaccine, COMIRNATY may not fully protect all those who receive it. Even after you/your child have had the vaccine, continue to follow the recommendations of local public health officials to prevent spread of COVID-19.

When it should not be used

You/your child should not receive COMIRNATY if:

  • you/your child are allergic to any of the ingredients in this vaccine (see What the medicinal ingredient is or What the non-medicinal ingredients are)
  • you/your child had a severe allergic reaction after a previous dose of this vaccine
  • you/your child have any symptoms that could be due to COVID-19. Talk with your/your child’s healthcare professional about your/your child’s symptoms and getting a COVID-19 test. Your/your child’s healthcare professional will advise you when you/your child are able to receive the vaccine.
What the medicinal ingredient is

Medicinal ingredient: mRNA

What the non-medicinal ingredients are

Non-medicinal ingredients: The non-medicinal ingredients differ depending on which version of the vaccine is given. If you are uncertain, check with your vaccination provider.

For 12 Years of Age or Older:

  • ALC-0315 = ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)
  • ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
  • 1,2-distearoyl-sn-glycero-3-phosphocholine
  • cholesterol
  • dibasic sodium phosphate dihydrate
  • monobasic potassium phosphate
  • potassium chloride
  • sodium chloride
  • sucrose
  • water for injection

For Age 5 Years to Less Than 12 Years:

  • ALC-0315 = ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)
  • ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
  • 1,2-distearoyl-sn-glycero-3-phosphocholine
  • cholesterol
  • sodium chloride
  • sucrose
  • tromethamine
  • tromethamine hydrochloride
  • water for injection
What dosage form it comes in

For 12 Years of Age and Older:
White to off-white suspension (to be diluted) provided in a multiple dose vial of 6 doses.

After dilution, the vial contains 6 doses of 0.3 mL, with 30 micrograms mRNA each.

For Age 5 Years to Less Than 12 Years:
White to off-white suspension (to be diluted) provided in a multiple dose vial of 10 doses.

After dilution, the vial contains 10 doses of 0.2 mL, with 10 micrograms mRNA each.

Warnings and precautions

To help avoid side effects and ensure proper use, talk to your/your child’s healthcare professional before you/your child receive COMIRNATY. Talk about any health conditions or problems you/your child may have, including if you/your child:

  • have had any problems following a previous dose of COMIRNATY such as an allergic reaction or breathing problems
  • have any allergies
  • have a weakened immune system due to a medical condition or are on a medicine that affects the immune system
  • have previously had episodes of myocarditis and/or pericarditis
  • are feeling nervous about the vaccination process or have ever fainted in association with an injection
  • have a bleeding problem, bruise easily or use a blood thinning medication
  • are pregnant, think you may be pregnant or plan to become pregnant
  • are breast-feeding

Other warnings you should know about:
It may take until 7 days after the second dose of COMIRNATY to develop protection against COVID-19. As with any vaccine, COMIRNATY may not fully protect all those who receive it.

Some of the effects of vaccination mentioned under “Side effects and what to do about them” may temporarily affect your ability to drive or use machines. Wait until these effects have worn off before you drive or use machines.

Interactions with this medication

Tell your/your child’s healthcare professional about all the medicines you/your child take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

There is no information on the use of COMIRNATY with other vaccines.

Tell your healthcare professional if you/your child have recently received any other vaccine.

Proper use of this medication

How COMIRNATY is given:

Usual dose:

For 12 Years of Age and Older:
COMIRNATY is given after dilution as an injection of 0.3 mL, preferably into a muscle of the upper arm.

You/your child will receive 2 injections, given 3 weeks apart. It is very important to return for the second injection, or the vaccine may not work as well.

A booster dose of COMIRNATY may be given at least 6 months after completion of the primary series in individuals 18 years of age and older.

For Age 5 Years to Less Than 12 Years:
COMIRNATY is given after dilution as an injection of 0.2 mL, preferably into a muscle of the upper arm.

Your child will receive 2 injections, given 3 weeks apart. It is very important that they return for the second injection, or the vaccine may not work as well.

If you have any further questions on the use of COMIRNATY, ask your healthcare professional.

Overdose:

In the event of suspected overdose with COMIRNATY, contact your regional poison control centre.

Missed Dose

If you forget to go back to your healthcare professional at the scheduled time for your/your child’s next dose, ask your/your child’s healthcare professional for advice.

Side effects and what to do about them

Like all vaccines, COMIRNATY can cause side effects, although not everybody gets them.

Side effects may occur at the following frequencies:

Very common: may affect more than 1 in 10 people

  • injection site pain, swelling
  • tiredness
  • headache
  • muscle pain
  • chills
  • joint pain
  • fever
  • diarrhea

Common: may affect more than 1 in 100 and up to 1 in 10 people

  • injection site redness
  • nausea
  • vomiting

Uncommon: may affect more than 1 in 1000 and up to 1 in 100 people

  • enlarged lymph nodes
  • feeling unwell
  • arm pain
  • feeling weak or lack of energy/sleepy
  • decreased appetite
  • excessive sweating
  • night sweats

Non-severe allergic reactions (such as rash, itching, hives or swelling of the face), severe allergic reactions and facial paralysis / Bell’s palsy have been reported.

These are not all the possible side effects you/your child may have when taking COMIRNATY. If you/your child experience any side effects not listed here, tell your/your child’s healthcare professional.

There is a remote chance that COMIRNATY could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of COMIRNATY. For this reason, the vaccination provider may ask you/your child to stay at the place where the vaccine was received for monitoring after vaccination. Should you/your child develop any serious symptoms or symptoms that could be an allergic reaction, seek medical attention right away. Symptoms of an allergic reaction include:

  • hives (bumps on the skin that are often very itchy)
  • swelling of the face, tongue or throat
  • difficulty breathing
  • a fast heartbeat
  • dizziness and weakness

If you/your child experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.

Your/your child’s health care provider should inform your local public health department of any serious side effects after vaccination.

How to store

COMIRNATY should be stored, supplied and administered by a healthcare professional.

Keep out of reach and sight of children.

Reporting side effects

Reporting Suspected Side Effects for Vaccines

For the general public: Should you experience a side effect following immunization, please report it to your healthcare professional.

Should you require information related to the management of the side effect, please contact your healthcare professional. The Public Health Agency of Canada, Health Canada and and ModernaTX, Inc. cannot provide medical advice.

For healthcare professionals: If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory (https://www.canada.ca/en/public-health/services/immunization/reporting-adverse-events-following-immunization/form.html ) and send it to your local Health Unit.

More information

If you want more information about COMIRNATY:

This leaflet was prepared by Pfizer Canada ULC.

Last Revised: November 19, 2021

Report a problem on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, please contact us.

Date modified: